You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Effect of Intravitreal Ranibizumab on Corneal Endothelium in Age-Related Macular Degeneration

Pérez-Rico, Consuelo PhD, MD*; Benítez-Herreros, Javier MD*; Castro-Rebollo, María MD*; Gómez-SanGil, Yanira MD*; Germain, Francisco PhD, MD†; Montes-Mollón, María Ángeles MD*; Teus, Miguel Ángel PhD, MD*

Cornea:
doi: 10.1097/ICO.0b013e3181ca33d2
Clinical Science
Abstract

Purpose: To determine the effect of intravitreal injection of ranibizumab on the corneal endothelium in patients with choroidal neovascularization in age-related macular degeneration.

Methods: Observational prospective case series study. Fifty-two eyes of 52 consecutive patients (29 men, 23 women; age range, 61-80 years) were evaluated. All participants received monthly intravitreal injections of (0.05 mL, 0.5 mg) ranibizumab for 3 consecutive months; the follow-up period was 6 months. Central corneal specular microscopy was performed before injection and at 7 days and 6 months after the first intravitreal injection. The endothelial cell density, coefficient of variation of cell size, and percentage of hexagonal cells were analyzed, and the central corneal thickness was measured.

Results: There were no significant differences in the endothelial cell densities, coefficient of variation of cell sizes, and percentage of hexagonal cells values before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.987, P = 0.822, and P = 0.918, respectively). There was also no significant difference in central corneal thickness measurements before injection and at 7 days and 6 months after the first intravitreal ranibizumab injection (P = 0.325).

Conclusion: Repeated intravitreal injections of 0.5 mg of ranibizumab do not seem to cause substantial changes in the corneal endothelium at 6 months.

Author Information

From the *Department of Ophthalmology, University Hospital Principe de Asturias; and †Department of Physiology, School of Medicine, University of Alcalá, Alcalá de Henares (Madrid), Spain.

Received for publication June 15, 2009; revision received October 23, 2009; accepted November 1, 2009.

Supported by the Fundación de Investigación del Hospital Universitario Principe de Asturias, Fundación para la Investigación Biomédica del Hospital Universitario Principe de Asturias, and Instituto de Salud Carlos III (RD07/0062/0008).

Competing Interests: None.

Reprints: Consuelo Pérez-Rico, MD, Department of Ophthalmology, University Hospital Principe de Asturias, University of Alcalá, Carretera Alcalá-Meco s/n 28805 Alcalá de Henares (Madrid), Spain (e-mail: cinta.perezrico@gmail.com).

© 2010 Lippincott Williams & Wilkins, Inc.